'Off-the-shelf' allogeneic CAR T cells: development and challenges.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Autologous chimeric antigen receptor (CAR) T cell therapy has transformed blood cancer treatment.
• Allogeneic CAR T cells present potential benefits including immediate availability, product standardization, and cost reduction through industrial processes.

Purpose of the Study:

• To review T cell sources for optimal allogeneic CAR T cell therapy.
• To describe technological approaches, primarily gene editing, for producing allogeneic CAR T cells with reduced graft-versus-host disease (GvHD) potential.

Main Methods:

• Review of current literature on T cell sources for allogeneic CAR T cell therapy.
• Analysis of gene editing technologies for modifying allogeneic CAR T cells to mitigate GvHD.

Main Results:

• Allogeneic CAR T cells face challenges including potential GvHD and rapid host immune elimination.
• Next-generation allogeneic CAR T cells are being developed to overcome these limitations.

Conclusions:

• Improved allogeneic CAR T cell products hold promise for advancing cancer treatment.
• Gene editing technologies are crucial for developing safer and more effective allogeneic CAR T cell therapies.